Lytix Biopharma

Description

Lytix Biopharma develops the ruxotemitide (LTX-315) oncolytic molecule program, building intratumoral peptide-based therapies that lyse cancer cell membranes and induce abscopal anti-tumor immune responses for neoadjuvant treatment of solid tumors.

Lytix Biopharma is located in the Oslo ecosystem.

Related

• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• 21st.BIO21st.BIO A/S provides precision fermentation technology for proteins and peptides, using microbial strains, fermentation processes, and…
• 3H Biomedical3H Biomedical supplies primary human and animal cell-based products, RNA, DNA, assays and culture media for life science research, drug…
• AbbelightAbbelight provides an integrated bioimaging workflow combining advanced microscopy and nanoscopy platforms, ready-to-use reagents, and NEO…
• Ability PharmaAbility Pharma develops oral targeted anticancer compounds that induce cytotoxic autophagy in cancer cells and advances clinical-stage…
• AACD PharmaACD Pharma develops bacteriophage-based biocontrol products and technologies for preventing and treating bacterial infections, with…
• AciesBioAciesBio provides microbial biotech services for strain engineering, scale-up process design, fermentation-broth processing, contract…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…
• Actival SAActival SA develops patient-specific active dental appliances and 3D-printed dental products that integrate patented microchannel…